Immune activation and immune-associated neurotoxicity in Long-COVID: A systematic review and meta-analysis of 103 studies comprising 58 cytokines/chemokines/growth factors
Brain Behavior and Immunity,
Год журнала:
2024,
Номер
122, С. 75 - 94
Опубликована: Авг. 9, 2024
Язык: Английский
Towards an understanding of physical activity-induced post-exertional malaise: Insights into microvascular alterations and immunometabolic interactions in post-COVID condition and myalgic encephalomyelitis/chronic fatigue syndrome
Infection,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 6, 2024
Язык: Английский
Long COVID: cognitive, balance, and retina manifestations
Frontiers in Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Июль 5, 2024
Background
The
neurological
symptoms
of
Long
COVID
(LC)
and
the
impact
neuropsychological
manifestations
on
people’s
daily
lives
have
been
extensively
described.
Although
a
large
body
literature
describes
symptoms,
validating
this
with
objective
measures
is
important.
This
study
aims
to
identify
describe
effects
cognition,
balance,
retinal
fundus,
determine
whether
duration
influences
cognitive
impairment.
Methods
cross-sectional
involved
LC
volunteers
complaint
from
public
health
centers
in
northern
Barcelona
who
participated
between
January
2022
March
2023.
collected
sociodemographic
characteristics,
information
substance
use,
comorbidities,
clinical
data
related
COVID-19.
We
measured
five
domains
using
battery
tests.
Balance
was
assessed
through
posturography
vascular
involvement
by
retinography.
Results
A
total
166
people
complaints
participated,
80.72%
were
women
mean
age
49.28
±
8.39
years.
most
common
self-reported
concentration
memory
deficit
(98.80%),
brain
fog
(82.53%)
insomnia
(71.17%).
68.67%
presented
at
least
one
domain,
executive
functions
being
frequent
(43.98%).
51.52%
participants
exhibited
dysfunctional
pattern
9.2%
showed
some
alteration
retina.
There
no
statistically
significant
differences
impairment
symptom
duration.
Conclusion
Our
findings
contribute
more
comprehensive
understanding
pathology
associated
COVID.
They
highlight
diversity
presence
abnormal
balance
patterns,
These
underscore
necessity
addressing
management
condition
primary
care
follow-up
pursuit
multidisciplinary
treatment.
Язык: Английский
Cardiac structure and function 1.5 years after COVID-19: results from the EPILOC study
Infection,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 24, 2025
Impaired
left
and
right
ventricular
(LV/RV)
function
during
acute
SARS-CoV-2
infection
has
been
predominantly
reported
in
hospitalized
patients,
but
long-term
cardiac
sequelae
large,
well-characterized
cohorts
remain
inconclusive.
This
study
evaluated
structure
individuals
with
post-Coronavirus
disease
(COVID)
syndrome
(PCS)
compared
to
recovered
controls
(CON),
focusing
on
associations
cardiopulmonary
symptoms
rapid
physical
exhaustion
(RPE).
multicenter,
population-based
included
1154
participants
(679
PCS,
475
age-
sex
matched
CON;
mean
age
49
±
12
years;
760
women)
1.5
years
post-infection.
Transthoracic
echocardiography
assessed
LV
global
longitudinal
strain
(GLS),
RV
GLS
free
wall
(FWS),
other
measures.
Cardiopulmonary
exercise
testing
(CPET)
measured
maximum
respiratory
oxygen
uptake
(VO2max)
as
a
marker
of
fitness.
PCS
exhibited
significantly
lower
(-20.25%
[-21.28
-
-19.22]
vs.
-20.73%
[-21.74
-19.72],
p
=
0.003),
reduced
diastolic
(E/A
1.16
[1.04-1.27]
1.21
[1.1-1.32],
0.022)
decreased
TAPSE
(24.45
mm
[22.14-26.77]
25.05
[22.78-27.32],
CON,
even
after
adjusting
for
confounders.
values
were
similar
between
groups.
correlated
inversely
VO2max
(p
0.004)
positively
RPE
0.050),
though
no
observed
symptoms.
demonstrates
subtle
yet
consistent
reductions
function,
specifically
capacity
CON.
While
these
changes
are
within
reference
ranges,
their
potential
impact
clinical
outcomes
warrants
further
investigation.
These
findings
highlight
the
need
assessments
follow-up
symptomatic
patients.
Язык: Английский
Variability in Arterial Stiffness and Vascular Endothelial Function After COVID-19 During 1.5 Years of Follow-Up—Systematic Review and Meta-Analysis
Life,
Год журнала:
2025,
Номер
15(4), С. 520 - 520
Опубликована: Март 21, 2025
Increasing
long-term
observations
suggest
that
coronavirus
disease
2019
(COVID-19)
vasculopathy
may
persist
even
1.5
years
after
the
acute
phase,
potentially
accelerating
development
of
atherosclerotic
cardiovascular
diseases.
This
study
systematically
reviewed
variability
brachial
flow-mediated
dilation
(FMD)
and
carotid-femoral
pulse
wave
velocity
(cfPWV)
from
phase
COVID-19
through
16
months
follow-up
(F/U).
Databases
including
PubMed,
Web
Science,
MEDLINE,
Embase
were
screened
for
a
meta-analysis
without
language
or
date
restrictions
(PROSPERO
reference
CRD42025642888,
last
search
conducted
on
1
February
2025).
The
quality
included
studies
was
assessed
using
Newcastle–Ottawa
Quality
Scale.
We
considered
all
(interventional
pre-post
studies,
prospective
observational
randomized,
non-randomized
trials)
FMD
cfPWV
in
adults
(aged
≥
18
years)
with
laboratory-confirmed
compared
non-COVID-19
controls
changes
these
parameters
during
F/U.
Twenty-one
reported
differences
FMD,
examined
between
patients
control
groups
various
stages:
acute/subacute
(≤30
days
onset),
early
(>30–90
days),
mid-term
(>90–180
late
(>180–270
very
(>270
days)
post-COVID-19
recovery.
Six
while
nine
did
so
Data
14
(627
cases
694
controls)
15
(578
703
our
meta-analysis.
showed
significant
decrease
to
(standardized
mean
difference
[SMD]=
−2.02,
p
<
0.001),
partial
improvements
noted
recovery
(SMD
=
0.95,
0.001)
0.92,
0.006).
Normalization
observed
0.12,
0.69).
In
contrast,
values,
which
higher
than
1.27,
remained
elevated
throughout
F/U,
no
except
(SMD=
−0.39,
0.001).
recovery,
values
those
0.45,
0.010).
manuscript,
we
discuss
how
factors,
severity
COVID-19,
persistence
syndrome,
patient’s
initial
vascular
age,
depending
metrics
age
risk
influenced
time
degree
improvement.
Язык: Английский
Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications
Journal of Cardiovascular Development and Disease,
Год журнала:
2025,
Номер
12(5), С. 171 - 171
Опубликована: Апрель 28, 2025
Non-traditional
cardiovascular
risk
factors
(RFs)
are
increasingly
emerging
as
important
modifiers
of
(CVR),
offering
insights
beyond
traditional
metrics
like
hypertension,
diabetes,
and
dyslipidemia.
These
include
novel
biomarkers,
chronic
conditions
(e.g.,
kidney
disease
obstructive
pulmonary
disease),
environmental
exposures,
inflammation,
infections,
psychosocial
factors,
sex-specific
conditions,
all
which
influence
the
prediction,
management,
outcomes
(CVD).
additional
RFs
may
impact
on
CVD
prediction
add
valid
information
during
tailored
patient
assessment
management.
Therefore,
a
careful
both
non-traditional
RFs,
with
personalized
treatment,
could
dramatically
reduce
total
burden.
Nevertheless,
further
research
is
needed
to
precisely
estimate
magnitude
their
prognosis
in
order
be
included
future
charts.
This
review
provides
critical
analysis
pathophysiological
mechanisms,
implications
for
care.
Integrating
these
into
CVR
can
reclassify
categories,
optimize
therapeutic
strategies,
improve
prognosis.
However,
refine
inclusion
charts
evaluate
public
health
outcomes.
A
tailored,
multidisciplinary
approach
essential
burden
associated
mortality.
Язык: Английский
Infection and pulmonary vascular diseases consortium: United against a global health challenge
Pulmonary Circulation,
Год журнала:
2024,
Номер
14(4)
Опубликована: Окт. 1, 2024
Abstract
Leveraging
the
potential
of
virtual
platforms
in
post‐COVID‐19
era,
Infection
and
Pulmonary
Vascular
Diseases
Consortium
(iPVDc),
with
support
Research
Institute
(PVRI),
launched
a
globally
accessible
educational
program
to
highlight
top‐notch
research
on
inflammation
infectious
diseases
affecting
lung
vasculature.
This
innovative
series
has
already
successfully
brought
together
distinguished
investigators
across
five
continents
–
Asia,
Europe,
South
North
America,
Africa.
Moreover,
these
open
global
forums
have
contributed
comprehensive
understanding
complex
interplay
among
immunology,
inflammation,
infection,
cardiopulmonary
health,
especially
concerning
pulmonary
hypertension
related
disorders.
These
enlightening
discussions
not
only
heightened
awareness
about
impact
various
pathogenic
microorganisms,
including
fungi,
parasites,
viruses,
onset
development
vascular
but
also
cast
spotlight
co‐infections
neglected
illnesses
like
schistosomiasis
‐
disease
that
continues
impose
heavy
socioeconomic
burden
numerous
regions
worldwide.
Thus,
overall
goal
this
review
article
is
present
most
recent
breakthroughs
from
PVDs
as
well
bring
light
scientific
insights
2023
iPVDc/PVRI
symposium
series,
shaping
our
crucial
health
issues
more
than
ever
interconnected
world.
Язык: Английский
The Relevance of the Endothelium in Cardiopulmonary Disorders
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(17), С. 9260 - 9260
Опубликована: Авг. 27, 2024
The
endothelium
is
a
cell
monolayer
that
lines
vessels
and
separates
tissues
from
blood
flow.
Endothelial
cells
(ECs)
have
multitude
of
functions,
including
regulating
flow
systemic
perfusion
through
changes
in
vessel
diameter.
When
an
injury
occurs,
the
affected
by
altering
its
functions
structure,
which
leads
to
endothelial
dysfunction,
characteristic
many
vascular
diseases.
Understanding
role
plays
pulmonary
cardiopulmonary
diseases,
exploring
new
therapeutic
strategies
utmost
importance
advance
clinically.
Currently,
there
are
several
treatments
able
improve
patients'
quality
life,
however,
none
effective
nor
curative.
This
review
examines
critical
vasculature,
investigating
alterations
occur
ECs
their
consequences
for
potential
molecular
targets
regulate
alterations.
Additionally,
we
delve
into
promising
non-pharmacological
strategies,
such
as
exercise
diet.
significance
disorders
increasingly
being
recognized,
making
relevant
target
novel
therapies
aimed
at
preserving
functional
structural
integrity.
Язык: Английский
Perspective Chapter: The Cardiovascular Impact of COVID-19
IntechOpen eBooks,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 29, 2024
While
it
is
well-known
that
subjects
with
underlying
cardiovascular
disease
as
well
those
associated
comorbidities
have
an
increased
susceptibility
to
worse
outcomes
during
acute
COVID-19
infection,
the
long-term
impact
of
still
be
unravelled.
A
subset
patients
continues
present
cardiopulmonary
symptoms,
mainly
shortness
breath,
chest
pain
and
palpitations,
months
even
years
after
infection.
Furthermore,
studies
revealed
a
minority
residual
left
and/or
right
ventricular
dysfunction
at
follow-up,
deranged
cardiac
markers,
troponin
NT-proBNP
levels.
The
chapter
will
explore
current
evidence
regard
endothelial
myocardial
following
COVID-19,
discuss
possible
pathophysiology,
suggest
management
persistent
symptomatology.
Язык: Английский
Evaluating the Role of Calcium Dobesilate in COVID-19-Related Pulmonary Vascular Endotheliitis and Thrombosis: A Retrospective Analysis of Real-World Data
Luis Fernando Flota-Cervera,
Alejandra Arellano-Bárcenas,
José Luis Salazar-G
и другие.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Abstract
Background
SARS-CoV-2
(COVID-19)
infection
is
known
to
cause
acute
inflammatory
pulmonary
microangiopathy,
leading
alveolar-capillary
thrombosis,
severe
respiratory
failure,
and
potential
mortality.
This
study
aims
evaluate
the
efficacy
of
calcium
dobesilate
(CaD)
in
treating
COVID-19-related
complications
using
real-world
data.
Methods
retrospective
included
60
COVID-19
patients
treated
with
CaD
addition
standard
care
at
three
outpatient
centers
Mexico
City
Guadalajara.
Patient
data,
including
demographics,
medical
history,
symptoms,
concomitant
treatments,
were
collected
from
records.
Results
The
median
dose
was
2
grams
per
day,
starting
on
third
day
after
diagnosis
continuing
for
a
28
days.
Half
also
required
steroid
therapy,
14
receiving
dexamethasone
16
prednisone.
Additionally,
23.3%
oxygen
volumes
ranging
3
10
liters
minute.
Improvement
clinical
symptoms
observed
18.6
±
10.6
days
(n
=
50),
full
recovery
occurring
25.6
10.3
42).
Importantly,
no
deaths
or
long-term
reported
among
participants.
Conclusion
use
COVID-19-associated
microangiopathy
shows
promising
outcomes,
notable
absence
mortality
sequelae.
However,
future
randomized,
double-blind,
placebo-controlled
trials
larger
sample
sizes
are
essential
confirm
these
findings
establish
CaD's
role
management.
Язык: Английский